TXG at a glance
10x Genomics, Inc. (TXG, SEC CIK 1770787) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), 10x Genomics, Inc. (TXG) reported revenue of $642.8 million (up 5.2% from FY2024) and a net loss of $43.5 million. Diluted EPS was -$0.35.
- As of June 30, 2026, 34 institutional investment managers tracked by SignalX reported holding 10x Genomics, Inc. (TXG) shares worth $3.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Saxonov Serge on September 22, 2026 of 2,800 shares at $82.36 per share.
- In the last 90 days, TXG insiders reported 0 open-market purchases ($0) and 28 open-market sales ($12.2M) on Form 4, a net sale of $12.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $642.8M
- +5.2% vs prior year
- Insiders · 90 days
- 0 buys · 28 sells
- Net −$12.2M
- 13F holders
- 34 funds
- $3.0B · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
- New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
- Strategic emphasis on expanding spatial portfolio with Visium CytAssist instrument and new Xenium analyzer for in situ RNA analysis
- Employee count increased to 1,178 in 2025, including 332 in R&D and 473 in sales/marketing/support
- Noteworthy: Sold 1,007 instruments and 424,000 consumable reactions in 2025, reflecting growth in consumable reactions despite slight instrument sales decline vs 2024
Risk Factors
- Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
- Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
- Operational/supply chain risk: $7.8M increase in inventory write-downs due to product mix changes and manufacturing cost pressures in 2025
- Competitive/market disruption risk: Price declines of Spatial instruments caused 39% revenue drop ($35.9M) in 2025 amid competition and market pricing pressure
- Financial/structural risk: Dependence on contingent consideration of up to $30M from Scale Bio acquisition, with fair value remeasured quarterly causing revenue and income fluctuation
Management Discussion & Analysis
- Cash flow, buybacks, dividends, and capex data not included
- Forward-looking statements caution on risks and uncertainties without specific guidance
AI summary of the TXG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $151.0M, down 13% YoY from $172.9M, driven by license and royalty revenue falling 93% to $1.9M
- Gross margin 74% vs 72% YoY; gross profit $112.5M vs $125.1M
- Best segment Spatial consumables $42.3M, up 16%; worst Spatial instruments $4.6M, down 48%
- Cash and securities $552.0M, up $28.6M; operating cash flow $43.1M vs $52.1M YoY
- Outlook: 2026 revenue expected to moderately increase excluding litigation revenue; operating expenses expected to modestly decrease
Risk Factors
- No material changes to previously disclosed 10-K risk factors
- No newly added quarterly risk factor or identified trigger
- No new regulatory, legal, or compliance risk disclosed
- No updated operational, competitive, or market risk disclosed
- No updated liquidity, debt, currency, or concentration risk disclosed
AI summary of the TXG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the financial results and management commentary
Item 5.07: Submission of Matters to a Vote of Security Holders
- 90.5% vote participation established a quorum for the June 4, 2026 annual meeting
- Serge Saxonov, Benjamin J. Hindson, and John R. Stuelpnagel elected to three-year terms expiring in 2029
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release attached as Exhibit 99.1 for revenue, earnings, guidance, and operating details
AI summaries of TXG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TXG
Don't miss the next TXG filing
- Alerts as it files. A push when TXG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TXG, by share count.
- Ask anything. An AI agent that reads every TXG filing and answers with sources.
TXG alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Saxonov Serge | Sell | Sep 22, 2026 | 2,800 | $82.36 |
| Saxonov Serge | Sell | Sep 22, 2026 | 2,000 | $79.62 |
| Saxonov Serge | Sell | Sep 22, 2026 | 9,300 | $80.90 |
| Saxonov Serge | Sell | Sep 22, 2026 | 9,900 | $81.83 |
| Saxonov Serge | Sell | Sep 22, 2026 | 1,000 | $78.23 |
| SULIMAN SHEHNAAZ | Sell | Sep 22, 2026 | 614 | $79.51 |
| SULIMAN SHEHNAAZ | Sell | Sep 22, 2026 | 292 | $78.20 |
| SULIMAN SHEHNAAZ | Sell | Sep 22, 2026 | 2,270 | $81.67 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $618.7M | $610.8M | $642.8M |
| Gross Profit | - | $414.5M | $443.9M |
| Operating Income | - | -$194.6M | -$61.0M |
| Net Income | - | -$182.6M | -$43.5M |
| Gross Margin | - | 67.9% | 69.1% |
| Op. Margin | - | -31.9% | -9.5% |
| Net Margin | - | -29.9% | -6.8% |
| Balance Sheet | |||
| Total Assets | - | $918.6M | $1.0B |
| Equity | - | $710.1M | $796.3M |
| ROE | - | -25.7% | -5.5% |
| Per Share | |||
| EPS | - | $-1.52 | $-0.35 |
| Cash Flow | |||
| Operating CF | - | $6.7M | $136.1M |
| CapEx | $48.6M | $12.4M | $5.9M |
Source: XBRL data in 10x Genomics, Inc. (TXG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TXG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 34 | $2.97B |
| Q1 2026 | 34 | $1.58B |
| Q4 2025 | 29 | $1.15B |
| Q3 2025 | 31 | $827.1M |
| Q2 2025 | 30 | $792.0M |
| Q1 2025 | 26 | $482.9M |
| Q4 2024 | 20 | $658.3M |
| Q3 2024 | 19 | $423.9M |
- T. Rowe Price Group+4.38M (+2681%)
- Citadel Advisors LLC+2.04M (+274%)
- BlackRock+724.2K (+7%)
- Morgan Stanley+695.6K (+26%)
- State Street Corp+212.6K (+8%)
- Millennium Management−1.95M (-94%)
- ARK Investment Management−1.71M (-15%)
- Goldman Sachs Group−822.9K (-21%)
- AQR Capital Management−511.8K (-20%)
- Two Sigma Investments−260.7K (-65%)
- Allstate+7.0K
- Marex Group plc−35.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 223 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TXG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 24, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| SC 13G | Sep 8, 2026 | - | - | |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - |
Related Health Care companies
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
TXG SEC filings: frequently asked questions
Are TXG insiders buying or selling?
In the last 90 days, 10x Genomics, Inc. (TXG) officers, directors and 10% owners reported no open-market purchases and 28 open-market sales worth $12.2 million by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TXG stock?
As of June 30, 2026, the largest 10x Genomics, Inc. (TXG) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($675.9 million), BlackRock ($414.2 million), ARK Investment Management ($383.5 million), Vanguard Portfolio Management LLC ($267.7 million), Vanguard Capital Management LLC ($194.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TXG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), 10x Genomics, Inc. (TXG) reported revenue of $642.8 million (up 5.2% from FY2024) and a net loss of $43.5 million. Diluted EPS was -$0.35. The figures come from the XBRL data in the 10-K.
What are the main risks in TXG's latest 10-K?
In the 10-K filed February 13, 2026, 10x Genomics, Inc. (TXG) flagged: Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue. Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025. (AI summary of the Risk Factors section.)
What did TXG report in its latest 8-K?
10x Genomics, Inc. (TXG) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest TXG SEC filings?
10x Genomics, Inc. (TXG) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 24, 2026.
What is TXG's SEC CIK number?
10x Genomics, Inc. (TXG)'s SEC Central Index Key (CIK) is 1770787. EDGAR lists every TXG filing under that number.
Ask anything about TXG
The research agent reads TXG's filings, financials, insider trades and 13F holders, then answers with sources.